Ariad Pharmaceuticals News
ARIAD Honored with Gold Stevie® Awards as Pharmaceutical Company of the Year at 2013 American Business AwardsBusiness Wire Jun 18
ARIAD Pharmaceuticals, Inc. today announced that it was honored with two Gold Stevie® Awards in the categories of Company of the Year, Pharmaceuticals and Executive of the Year, Pharmaceuticals.
The study will evaluate Iclusig's efficacy and safety in patients who have failed at least one tyrosine kinase inhibitor therapy.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 13, 2013-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Annual Meeting of Stockholders will be webcast live on June 20, 2013 and can be accessed ...
Ariad Pharmaceuticals Inc. Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 02:40 PMSeeking Alpha Jun 11
Ariad Pharmaceuticals Inc. Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 02:40 PM
Ash Stevens, Inc. , a leading provider of global contract pharmaceutical drug substance development and API manufacturing services, announces the U.S. Food and Drug Administration has approved ASI's manufacturing ...
ARIAD Announces Initiation of Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal TumorsBusiness Wire Jun 11
ARIAD Pharmaceuticals, Inc. today announced the initiation of the Phase 2 trial of Iclusig® in adult patients with metastatic and/or unresectable gastrointestinal stromal tumors .
ARIAD Pharmaceuticals, Inc. today announced that it will provide an overview of the Company’s business at two upcoming investor conferences being held next week: